Research and Clinical Trials

Brief Description  
Treatment for recurrent glioblastoma or gliosarcoma, who are resistant to temodar.
Who may be Eligible  

Patients must meet the following inclusion criteria to be eligible to enter the study:

  • Histology proven recurrent intracranial glioblastoma or gliosarcoma
  • Must have completed radiation therapy for phase 1 and at least 2 adjuvant cycles of temodar for the Phase II component
  • History & physical and neurological
  • MRI scans
  • Blood tests (liver, kidney and blood counts) and pregnancy test if indicated
  • Patients with unstable cardiac disease, recent MI, COPD and bleeding disorders are not  eligible
  • age greater or equal to 18 years
  • no prior invasive malignancy within the past 3 years
IRB Number  
Principal Investigator  
Haggstrom, Daniel

For More Information, Contact  Donna  , Couture-Johnson
Phone:  (704) 355-1677  Fax:  (704) 355-1188  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC